About Juno Therapeutics
Juno Therapeutics is a company based in Seattle (United States) founded in 2013 was acquired by Q Therapeutics in May 2025.. Juno Therapeutics has raised $316.67 million across 5 funding rounds from investors including Crestline, Celgene and Arch Venture Partners. The company has 520 employees as of December 31, 2017. Juno Therapeutics has completed 4 acquisitions, including AbVitro, Stage Cell Therapeutics and X-Body Biosciences. Juno Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Seattle, United States
- Employees 520 as on 31 Dec, 2017
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Juno Therapeutics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
394 people
Software Development Team
340 people
Senior Team
99 people
Product Management Team
97 people
Operations Team
83 people
Data Analysis and Operations Team
60 people
Sales and Marketing
58 people
Human Resources and Administration
45 people
Unlock access to complete
Funding Insights of Juno Therapeutics
Juno Therapeutics has successfully raised a total of $316.67M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $31.09 million completed in October 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $31.1M
-
First Round
First Round
(26 Dec 2013)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2017 | Amount | Post-IPO - Juno Therapeutics | Valuation |
investors |
|
| Jun, 2017 | Amount | Post-IPO - Juno Therapeutics | Valuation |
investors |
|
| Aug, 2014 | Amount | Series B - Juno Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Juno Therapeutics
Juno Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Crestline, Celgene and Arch Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location | |
|
Investment management and philanthropic ventures linked to Bezos Expeditions.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Juno Therapeutics
Juno Therapeutics has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include AbVitro, Stage Cell Therapeutics and X-Body Biosciences. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutic targets and antibodies are identified via immune sequencing technology.
|
2012 | ||||
|
Electrical Muscle Stimulation
|
2010 | ||||
|
Monoclonal antibodies are developed using proprietary discovery and screening systems.
|
2008 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Juno Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Juno Therapeutics Comparisons
Competitors of Juno Therapeutics
Juno Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Juno Therapeutics
Frequently Asked Questions about Juno Therapeutics
When was Juno Therapeutics founded?
Juno Therapeutics was founded in 2013.
Where is Juno Therapeutics located?
Juno Therapeutics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is Juno Therapeutics a funded company?
Juno Therapeutics is a funded company, having raised a total of $316.67M across 5 funding rounds to date. The company's 1st funding round was a Series B of $134M, raised on Dec 26, 2013.
How many employees does Juno Therapeutics have?
As of Dec 31, 2017, the latest employee count at Juno Therapeutics is 520.
What does Juno Therapeutics do?
Juno Therapeutics was founded in 2013 in Seattle, United States, within the biotechnology sector. T cell-based immunotherapies for cancer are developed using chimeric antigen receptor and high-affinity T cell receptor technologies, by which T cells are genetically engineered to identify and destroy cancer cells. Lead programs target acute lymphoblastic leukemia and adult B-cell malignancies. Additional initiatives address acute myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkins lymphoma, and non-small cell lung cancer.
Who are the top competitors of Juno Therapeutics?
Juno Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
How many acquisitions has Juno Therapeutics made?
Juno Therapeutics has made 4 acquisitions, including AbVitro, Stage Cell Therapeutics, and X-Body Biosciences.
Who are Juno Therapeutics's investors?
Juno Therapeutics has 7 investors. Key investors include Crestline, Celgene, Arch Venture Partners, Alaska Permanent Fund, and Bezos Expeditions.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.